Pharmacokinetics of infigratinib and its active metabolites in Chinese patients with advanced gastric cancer harboring FGFR2 gene amplification

Pharmacokinetics of infigratinib and its active metabolites in Chinese patients with advanced gastric cancer harboring FGFR2 gene amplification

Abstract Infigratinib, an FGFR1‐3 selective oral tyrosine kinase inhibitor, has shown clinical activity in cancers with FGFR alterations. The pharmacokinetics (PK) of infigratinib and its major metabolites have been characterized in global populations. This study examined the PK profile of infigrati...

Full description

Saved in:
Bibliographic Details
Main Authors: Jiajia Yuan, Lin Shen, Tian Shu Liu, HuiTing Xu, Jianwei Yang, Jia Wei, Haiping Jiang, Yanhong Deng, Hongming Pan, Yusheng Wang, Xiaotian Zhang, Zhi Peng, Changsong Qi, Lingli Zhang, Peiwen Hsu, Lin Song, Lei Mu, Qiao Sun, Jifang Gong, Cheng Lyu
Format: Article
Language:English
Published: Wiley 2024-12-01
Series:Clinical and Translational Science
Online Access:https://doi.org/10.1111/cts.70091
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1111/cts.70091

Similar Items